These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29285035)

  • 41. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance.
    Shtivelband MI
    Breast; 2013 Aug; 22(4):405-10. PubMed ID: 23499266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
    Johnston SR
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26251289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
    Gombos A; Barthélémy P; Awada A
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):823-34. PubMed ID: 25659402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
    Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
    JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
    Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.
    de Oliveira Taveira M; Nabavi S; Wang Y; Tonellato P; Esteva FJ; Cantley LC; Wulf GM
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1255-1262. PubMed ID: 28247034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.
    Paplomata E; O'Regan R
    Ther Clin Risk Manag; 2013; 9():27-36. PubMed ID: 23345981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
    Hurvitz SA; Kalous O; Conklin D; Desai AJ; Dering J; Anderson L; O'Brien NA; Kolarova T; Finn RS; Linnartz R; Chen D; Slamon DJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):669-80. PubMed ID: 25663547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer.
    Kimura M; Hanamura T; Tsuboi K; Kaneko Y; Yamaguchi Y; Niwa T; Narui K; Endo I; Hayashi SI
    Oncotarget; 2018 Apr; 9(30):21468-21477. PubMed ID: 29765553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
    Fedele P; Calvani N; Marino A; Orlando L; Schiavone P; Quaranta A; Cinieri S
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):243-51. PubMed ID: 22494933
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer.
    Zhou D; Ouyang Q; Liu L; Liu J; Tang Y; Xiao M; Wang Y; He Q; Hu ZY
    Transl Oncol; 2019 May; 12(5):764-774. PubMed ID: 30893632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.
    Almstedt K; Schmidt M
    Breast Care (Basel); 2015 Jul; 10(3):168-72. PubMed ID: 26557821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.
    Stringer EM; Fleming GF
    Eur Endocrinol; 2013 Mar; 9(1):18-21. PubMed ID: 30349605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting clinical response to everolimus in ER+ breast cancers using machine-learning.
    Nath A; Cosgrove PA; Chang JT; Bild AH
    Front Mol Biosci; 2022; 9():981962. PubMed ID: 36304922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus.
    Arora S; Akhil R; Chacko RT; George R
    Indian J Med Paediatr Oncol; 2016; 37(2):116-8. PubMed ID: 27168711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review of the endocrine resistance in hormone-positive breast cancer.
    Chien TJ
    Am J Cancer Res; 2021; 11(8):3813-3831. PubMed ID: 34522451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.